Clinical Trial: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Study Status: Completed
Recruit Status: RECRUITING
Condition: Hidradenitis Suppurativa
Study Type: INTERVENTIONAL
Official Title: A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Brief Summary:
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development.The study will last approximately 62 weeks and may include up to 31 visits.
Read more